Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew R Smith

Showing results (141-150 of 319) with videos related to

Pageof 32
Sort By:
European Urology|February 17, 2012
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolismJim C Hu, Stephen B Williams, A James O'Malley, et al.
The Journal of Urology|January 17, 2012
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancerAlicia K Morgans, Michael L Hancock, K Gary Barnette, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Urology|September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancerMatthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancerRichard J Cook, Robert Coleman, Janet Brown, et al.
European Urology|December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancersPhilip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02Matthew R Smith, Kyounghwa Bae, Jason A Efstathiou, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Cancer|November 14, 2007
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31Jason A Efstathiou, Kyounghwa Bae, William U Shipley, et al.
European Urology|February 5, 2008
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02Jason A Efstathiou, Kyounghwa Bae, William U Shipley, et al.
Pageof 32

Showing results (141-150 of 319) with videos related to

Sort By:
Pageof 32
European Urology|February 17, 2012
Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolismJim C Hu, Stephen B Williams, A James O'Malley, et al.
The Journal of Urology|January 17, 2012
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancerAlicia K Morgans, Michael L Hancock, K Gary Barnette, et al.
Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research|September 8, 2011
Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Urology|September 11, 2007
Predictors of skeletal complications in men with hormone-refractory metastatic prostate cancerMatthew R Smith, Richard J Cook, Robert Coleman, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancerRichard J Cook, Robert Coleman, Janet Brown, et al.
European Urology|December 4, 2012
New and emerging therapies for bone metastases in genitourinary cancersPhilip J Saylor, Andrew J Armstrong, Karim Fizazi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2008
Diabetes and mortality in men with locally advanced prostate cancer: RTOG 92-02Matthew R Smith, Kyounghwa Bae, Jason A Efstathiou, et al.
The Journal of Urology|October 20, 2009
Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancerMatthew R Smith, Fred Saad, Blair Egerdie, et al.
Cancer|November 14, 2007
Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31Jason A Efstathiou, Kyounghwa Bae, William U Shipley, et al.
European Urology|February 5, 2008
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02Jason A Efstathiou, Kyounghwa Bae, William U Shipley, et al.
Pageof 32